Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and
tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to
placebo, as well as the pharmacokinetics of QGC001 and its metabolite EC33 and the
pharmacodynamic properties of QGC001 (effects on the renin-angiotensin-aldosterone system,
blood pressure and heart rate) in healthy male subjects.